An owner's guide to hyperbaric oxygen therapy.

Boyle's Law — gas volume decreases as pressure increases. Inside a pressurized chamber, any gas trapped in the body (sinuses, middle ear, gut, lungs) compresses on the way in and re-expands on the way out. This is why ear-clearing matters.

Henry's Law — gas dissolves into liquid in proportion to the partial pressure of that gas above the liquid. With supplemental oxygen at elevated pressure, dissolved oxygen in blood plasma rises 10–20× baseline. For the first time, oxygen delivery becomes independent of hemoglobin — plasma alone can carry enough.

The downstream cascade — sustained over a course of sessions, elevated tissue oxygen drives:

• Angiogenesis — new capillary growth in oxygen-starved tissue
• Stem-cell mobilization from bone marrow into circulation
• Mitochondrial biogenesis — new energy machinery in cells
• A measured shift toward anti-inflammatory cytokine profiles
• Up-regulation of antioxidant enzymes (SOD, catalase, glutathione peroxidase) — the "hyperoxic-hypoxic paradox"

Effects are largely cumulative and biological, not sensory. Many users feel little during a session. The work happens between sessions.

Tier one — FDA-cleared and UHMS-approved. The Undersea & Hyperbaric Medical Society recognizes fourteen approved indications. All of them use rigid hard-shell chambers at 2.0–3.0 ATA — well above home wellness pressures.

• Air or gas embolism · 2.8 ATA
• Carbon monoxide poisoning · 2.5–3.0 ATA
• Decompression sickness · 2.8 ATA
• Gas gangrene (clostridial myonecrosis) · 3.0 ATA
• Crush injury, compartment syndrome, acute traumatic ischemia · 2.0–2.5 ATA
• Selected non-healing wounds (diabetic foot ulcers, etc.) · 2.0–2.5 ATA
• Severe anemia (when transfusion is not possible)
• Intracranial abscess · 2.0–2.5 ATA
• Necrotizing soft tissue infections · 2.0–2.5 ATA
• Refractory osteomyelitis · 2.0–2.4 ATA
• Delayed radiation injury · 2.0–2.5 ATA
• Compromised skin grafts and flaps · 2.0–2.5 ATA
• Acute thermal burn injury · 2.0–2.4 ATA
• Idiopathic sudden sensorineural hearing loss (within 14 days) · 2.0–2.5 ATA
• Central retinal artery occlusion · 2.0–2.8 ATA

Tier two — emerging evidence, not FDA-cleared. Peer-reviewed studies — most at 1.5–2.0 ATA in rigid chambers — have produced encouraging results in:

• Persistent post-concussion / mild TBI — Harch et al. (2012, 2017, 2020) at 1.5 ATA, 40 sessions, with cognitive and SPECT improvements; Boussi-Gross et al. (PLOS ONE 2013) at 2.0 ATA
• Chronic-phase stroke recovery — Efrati et al. (PLOS ONE 2013) at 2.0 ATA, 40 sessions, 6–36 months post-stroke
• Fibromyalgia — Efrati et al. (PLOS ONE 2015) at 2.0 ATA, with documented brain SPECT changes
• Long COVID — Zilberman-Itskovich et al. (Scientific Reports 2022), randomized sham-controlled, 2.0 ATA, 40 sessions
• Age-related cognitive decline — Hadanny et al. (Aging 2020) at 2.0 ATA, 60 sessions, in healthy adults 64+
• Telomere length and senescent cell clearance — Hachmo et al. (Aging 2020) at 2.0 ATA — ~20% telomere lengthening after 60 sessions
• Inflammatory bowel disease (Crohn's, UC flares) — small RCTs at 2.0–2.4 ATA
• PTSD — Harch et al. at 1.5 ATA
• Acute migraine relief — Cochrane review at 2.0–2.4 ATA
• Sports recovery / DOMS — limited but suggestive at 2.0–2.5 ATA

Tier three — over-marketed or insufficient evidence. Treat these claims with skepticism:

• "Cures cancer" — unsupported; some adjuvant research exists but standalone treatment is not
• "Reverses aging" as a blanket claim — telomere data is one study, one biomarker
• Lyme disease — insufficient evidence, not UHMS-approved
• Multiple sclerosis — Cochrane review found no consistent benefit
• Cerebral palsy — Collet et al. (Lancet 2001) found no difference vs sham
• "Detoxifies" — no defined clinical mechanism or endpoint
• Mild HBOT (1.3 ATA) producing the same outcomes as 2.0 ATA studies — a common marketing leap

A 1.3 ATA session with 95% O₂ via mask delivers roughly half the dissolved oxygen of a 2.0 ATA session with 100% O₂. Both are real physiological doses; they are not interchangeable. The published clinical-trial outcomes from 2.0 ATA studies do not transfer one-for-one to 1.3 ATA chambers.

• 1.3 ATA (soft-shell portable) — mild HBOT. Lower risk profile, easier installation, no integrated oxygen pressurization. Evidence base is smaller; the strongest published 1.3 ATA data is in autism (mixed) and select neurological work
• 1.5 ATA (rigid) — the pressure of choice in much of Harch's mTBI / PTSD research
• 2.0 ATA (rigid) — the pressure of most modern wellness research (Tel Aviv group: stroke, fibromyalgia, long COVID, cognitive aging, telomeres)
• 2.4 ATA and above — clinical / FDA-cleared territory; oxygen toxicity risk rises sharply above 2.4 ATA, especially without air-break protocols

The right pressure depends on the use, the room, the budget, and the practitioner involved. The studio's job in a consultation is to match the chamber to the practice — not to push a higher number.

Pre-session — 30 to 60 minutes before.

• Hydrate — 16–20 oz of water; dehydration worsens fatigue and ear-clearing
• Eat lightly; avoid heavy meals or carbonated drinks (gas expands on decompression)
• No alcohol, no nicotine, for several hours prior
• Check ears and sinuses — if congested, use a decongestant (pseudoephedrine 30–60 min prior, or saline rinse) or skip the session
• Practice equalization — Valsalva, Toynbee (swallow with nose pinched), Frenzel, or simply yawning and swallowing
• Bathroom break — a 60–120 minute session is hard to interrupt
• Wear 100% cotton scrubs or loose cotton clothing — no synthetics (static), no makeup, no lotions, no hair products, no perfumes, no deodorants, no petroleum-based products

What not to bring inside.

• Phones, tablets, e-readers with lithium batteries (manufacturer-dependent — many soft chambers prohibit; check your model)
• Lighters, matches, anything battery-powered with exposed contacts
• Hand warmers (chemical heat)
• Petroleum jelly, Vicks, oil-based lip balms — use water-based alternatives (glycerin-based)
• Loose paper or tissues (combustion + concentrator filter risk)

What to bring. A water bottle (no carbonation), a book, an eye mask, downloaded audio via a Bluetooth speaker outside the chamber.

Compression — 5 to 15 minutes. Lie back, breathe normally. Equalize ears every few seconds as pressure rises — don't wait for pain. If ears won't clear, signal to stop or pause compression, sit up, swallow, try again. Expect a feeling of fullness, warmth, slight ear pop. The mask goes on once at-pressure (or per your chamber's protocol).

At-pressure — 60 to 90 minutes typical.

• Breathe normally through the mask for the prescribed time. Most 1.3 ATA protocols use continuous mask wear to deliver the 93–95% O₂
• At higher pressures (2.0 ATA+), some protocols include 5-minute air breaks every 20–30 minutes to reduce oxygen toxicity risk
• Read, listen, nap, meditate. Avoid moving around
• Keep mask seal tight — a leaky mask drops effective FiO₂ significantly
• Sip water

Decompression — 5 to 15 minutes. Ascent should be slow — at least 1–2 minutes per 0.1 ATA. Breathe normally; eustachian tubes vent passively on ascent, but yawning helps. Reverse block: if ear pain builds on the way out, signal to slow or pause — air trapped behind a blocked tube can cause worse barotrauma than on the way in. Gas in the gut may need to vent (normal).

Post-session. Sit up slowly; mild lightheadedness is normal. Drink 16+ oz of water. Avoid intense exercise for 30 minutes. Avoid flying or scuba diving for 12–24 hours after a high-pressure session. Mild fatigue, hunger, vivid dreams, or a deeper sleep that night are commonly reported.

• Loading phase — 20 to 40 sessions, 5 to 7 days a week, mirroring the Tel Aviv 60-session, 5×/week model. Most owners describe this as the "real" introduction to the chamber
• Maintenance — 1 to 3 sessions a week after loading
• Time of day — morning sessions can boost daytime energy; evening sessions improve sleep for many. Avoid right before bed if you find HBOT energizing
• Cycles vs continuous — cycling (e.g., 40 sessions, then 1–2 month break) is common; continuous use for years is also done. No long-term safety data exists for years-long daily use
• Don't double up — one session per day is the standard. Two-a-days raise oxygen toxicity risk and are reserved for clinical settings

Absolute contraindications — sessions should not occur:

• Untreated pneumothorax. Trapped air re-expands on decompression and can cause tension pneumothorax. The single most cited absolute contraindication
• Concurrent bleomycin chemotherapy. Risk of severe interstitial pneumonitis. Some centers allow HBOT >6 months post-bleomycin with risk discussion
• Doxorubicin (Adriamycin) — cardiotoxicity risk
• Cisplatin — impairs wound healing and DNA repair
• Disulfiram (Antabuse) — blocks superoxide dismutase, raising oxygen toxicity risk
• Mafenide acetate (Sulfamylon) topical — causes CO₂ buildup

Relative contraindications — physician clearance required:

• Uncontrolled seizure disorders (hyperoxia lowers the seizure threshold)
• Severe COPD with CO₂ retention or bullae (pneumothorax risk; loss of hypoxic respiratory drive)
• Uncontrolled high fever (lowers seizure threshold)
• Upper respiratory infections, sinusitis, severe congestion (barotrauma risk)
• Recent ear, sinus, or thoracic surgery
• History of spontaneous pneumothorax
• Severe claustrophobia
• Pregnancy — generally avoided for non-essential indications; CO poisoning is the exception
• Pacemakers, insulin pumps, neurostimulators — must be pressure-rated; check manufacturer specs
• Optic neuritis, advanced cataracts (hyperoxia may worsen)
• Congenital spherocytosis (severe hemolysis risk)

Common side effects.

• Middle ear barotrauma — most common (15–20% of users); pressure pain, fullness, possible TM rupture
• Sinus barotrauma — frontal/maxillary pain during compression
• Temporary myopia — refractive shift after 30+ session courses; usually reverses 6–12 weeks post-therapy. Documented at 2.0+ ATA, less likely at 1.3 ATA
• Cataract progression — with very long courses (>150 sessions)
• CNS oxygen toxicity — rare below 2.0 ATA. Signs: VENTID-C — Visual changes, Ear ringing, Nausea, Twitching, Irritability, Dizziness, Convulsions
• Pulmonary oxygen toxicity — substernal burning, dry cough; from prolonged exposure (rare in standard wellness protocols)
• Claustrophobia / anxiety — common in first 1–3 sessions, often resolves
• Fatigue or lightheadedness after a session
• Hypoglycemia in diabetics — HBOT can lower blood glucose by 30–50 mg/dL

Stop-session warning signs. If any of these appear, end the session — controlled depressurization or, if needed, emergency dump:

• Sharp, escalating ear or sinus pain not relieved by Valsalva
• Chest pain, shortness of breath, or coughing up blood
• Twitching (especially face), tunnel vision, ringing in ears, sudden nausea — the oxygen toxicity prodrome
• Seizure activity
• Severe panic that cannot be talked down
• Equipment malfunction — rapid pressure changes, oxygen concentrator alarm, smell of smoke or ozone

Drug interactions to know about. Beyond the absolute contraindications above: insulin and oral hypoglycemics (monitor blood glucose; dose adjustment likely), high-dose steroids (raise CNS oxygen toxicity risk), nicotine (vasoconstricts, reduces benefit; avoid same-day), alcohol (avoid before sessions — impairs equalization, dehydrates), anti-seizure medications (adherence is critical; missed doses raise seizure risk under hyperoxia).

Eliminate every ignition source within range of the chamber.

• Static electricity — 100% cotton clothing inside; synthetics generate static and burn aggressively in O₂
• Electronics, lithium batteries, lighters, sparking devices — none inside the chamber
• Mask exhaust enriches the immediate area — keep flammable materials, candles, heaters, and open flames at least 10 feet from the chamber and concentrator
• Use grounding straps if your chamber includes them
• No smoking in the room — ever. Residual oxygen lingers
• Smoke detector in the chamber room
• Class ABC fire extinguisher accessible
• Concentrator placed in a well-ventilated area — not in a closet, not against a wall (intake clearance required)

Emergency depressurization.

• Know the location of the dump valve before your first session
• For fire, smoke, medical emergency, or chamber malfunction — open the dump valve for controlled rapid descent
• Train a household member as your tender — they should be present or within earshot for every session
• Keep a phone outside the chamber with emergency contacts ready
• If the user inside loses consciousness — the tender depressurizes per manufacturer protocol (typically 1–3 minutes for soft chambers), opens the chamber, calls 911

Children, pets, multi-user chambers.

• Children should never operate a chamber alone. Supervision, equalization ability, and pediatric medical clearance are essential. Most manufacturers set a minimum age (often 5–8+)
• Pets are generally not recommended unless the chamber is veterinary-rated. Pets can't equalize or signal distress; fur generates static
• Multi-user soft chambers — if rated for two adults, both must be able to equalize independently. One person's claustrophobia or ear issue ends the session for both

The oxygen concentrator.

• Rinse the gross particle filter weekly; dry fully before reinstalling
• Replace HEPA / intake filter per manufacturer schedule (typically every 6–12 months)
• Replace zeolite sieve beds every 2–4 years, or sooner if O₂ output drops below 90% (verify monthly with an O₂ analyzer)
• Keep the intake clear; run the concentrator in a cool, dry environment — heat and humidity degrade sieve beds

The chamber itself.

• Wipe the interior with a mild, non-alcohol, non-petroleum cleaner after each session
• Inspect zippers, seams, and viewing windows monthly for wear
• Run a leak check monthly — pressurize, listen, soap-test seams. A pressure drop greater than 0.05 ATA in 5 minutes at full pressure suggests a leak — contact the studio
• Replace the breathing mask every 6–12 months, or when the seal degrades
• Replace mask tubing per manufacturer schedule
• Annual pressure-gauge calibration

Keep a logbook. Track session count, hours of operator time, and any anomaly. The log is useful for warranty conversations, insurance claims, and the practiced honesty a chamber asks for.

"More pressure is always better."
Dose-response is not linear. Above ~2.4 ATA, oxygen toxicity risk rises faster than benefit for most non-emergency indications. The Tel Aviv neuroplasticity protocols deliberately use 2.0 ATA, not higher.

"Mild HBOT at 1.3 ATA delivers the same benefits as 2.0 ATA chambers."
Plasma oxygen scales with partial pressure. A 1.3 ATA session with 95% O₂ delivers roughly half the dissolved O₂ of a 2.0 ATA session with 100% O₂. Some benefits may still occur, but extrapolating clinical-trial outcomes from 2.0 ATA studies to 1.3 ATA chambers is not directly supported by evidence.

"HBOT detoxifies the body."
No defined clinical mechanism; "detox" is not a measurable endpoint. HBOT does up-regulate antioxidant enzymes (SOD, catalase, glutathione peroxidase) over a course of treatment.

"You can't overdose on oxygen."
Oxygen toxicity is real and dose-dependent. CNS toxicity can cause seizures; pulmonary toxicity can cause lung injury. Risk is low at 1.3 ATA but rises sharply above 2.4 ATA, especially with prolonged exposure.

"HBOT is FDA-approved for [insert wellness claim]."
The FDA has cleared HBOT devices for fourteen specific medical indications. Wellness, anti-aging, recovery, and most off-label uses are not FDA-cleared, though they may be evidence-supported off-label uses.

"Oxygen makes cancer grow."
Mixed and oversimplified. Some preclinical work suggests HBOT may sensitize hypoxic tumors to radiation; other work suggests it doesn't accelerate growth in most cancers. Active malignancy warrants oncologist input, not blanket avoidance or blanket use.

"Soft chambers are toys; only hard chambers work."
Both are real medical devices with different dose ranges. Soft chambers deliver real but milder physiological effects. Hard chambers reach the pressures used in published clinical trials.

"I felt nothing, so it isn't working."
HBOT effects are largely cumulative and biological, not sensory. Many users report no acute sensation. Outcomes — when documented — are typically measured after 20–60 sessions, not session-by-session.

"Once I do a course, I'm done forever."
Effects, where documented, are not permanent. Telomere, cognitive, and tissue changes likely require maintenance protocols, though optimal maintenance dosing has not been established.